|
FR2338043A1
(fr)
|
1976-01-13 |
1977-08-12 |
Delmar Chem |
Derives de 4-arylpiperidine et procedes de production
|
|
US4132710A
(en)
|
1976-12-20 |
1979-01-02 |
Ayerst, Mckenna And Harrison, Ltd. |
[2]Benzopyrano[3,4-c]pyridines and process therefor
|
|
US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
IN164232B
(enExample)
|
1986-04-11 |
1989-02-04 |
Hoechst India |
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
JP2691986B2
(ja)
|
1987-08-28 |
1997-12-17 |
チッソ株式会社 |
ピリジン骨格を有する光学活性化合物の製造法
|
|
DE3743824C2
(de)
|
1987-12-23 |
1997-03-06 |
Hoechst Ag |
Verfahren zur enzymatischen Racematspaltung von racemischen Alkoholen mit/in Vinylestern durch Umesterung
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5284856A
(en)
|
1988-10-28 |
1994-02-08 |
Hoechst Aktiengesellschaft |
Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
|
|
DE3836676A1
(de)
|
1988-10-28 |
1990-05-03 |
Hoechst Ag |
Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
|
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
|
ES2096590T3
(es)
|
1989-06-29 |
1997-03-16 |
Medarex Inc |
Reactivos biespecificos para la terapia del sida.
|
|
US5804604A
(en)
|
1989-12-21 |
1998-09-08 |
Biogen, Inc. |
Tat-derived transport polypeptides and fusion proteins
|
|
US5670617A
(en)
|
1989-12-21 |
1997-09-23 |
Biogen Inc |
Nucleic acid conjugates of tat-derived transport polypeptides
|
|
ES2087997T3
(es)
|
1990-01-12 |
1996-08-01 |
Cell Genesys Inc |
Generacion de anticuerpos xenogenicos.
|
|
ATE116100T1
(de)
|
1990-08-09 |
1995-01-15 |
Francaise Coop Pharma |
Stabile natriumhypochloritlösung.
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
ES2108048T3
(es)
|
1990-08-29 |
1997-12-16 |
Genpharm Int |
Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
JPH0641075A
(ja)
|
1990-09-01 |
1994-02-15 |
Kazuo Achinami |
新規な１，４−ジヒドロピリジン化合物及びその製造方法
|
|
CA2064676A1
(en)
|
1991-04-02 |
1992-10-03 |
Manfred Schneider |
Immobilized biocatalyst, its preparation and use for ester synthesis in a column reactor
|
|
JPH06507398A
(ja)
|
1991-05-14 |
1994-08-25 |
リプリジェン コーポレーション |
Ｈｉｖ感染治療のための異種複合抗体
|
|
FI941572L
(fi)
|
1991-10-07 |
1994-05-27 |
Oncologix Inc |
Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
|
|
WO1993008829A1
(en)
|
1991-11-04 |
1993-05-13 |
The Regents Of The University Of California |
Compositions that mediate killing of hiv-infected cells
|
|
DE69333807T2
(de)
|
1992-02-06 |
2006-02-02 |
Chiron Corp., Emeryville |
Marker für krebs und biosynthetisches bindeprotein dafür
|
|
JPH07509137A
(ja)
|
1992-07-24 |
1995-10-12 |
セル ジェネシス，インク． |
異種抗体の生産
|
|
US6177401B1
(en)
|
1992-11-13 |
2001-01-23 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften |
Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
|
|
EP1005870B1
(en)
|
1992-11-13 |
2009-01-21 |
Biogen Idec Inc. |
Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
|
GB9422836D0
(en)
|
1994-11-11 |
1995-01-04 |
Wainscoat James |
Monitoring malignant disease
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
|
DK0821671T3
(da)
|
1995-04-20 |
2001-04-23 |
Pfizer |
Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
|
|
EP0822830B1
(en)
|
1995-04-27 |
2008-04-02 |
Amgen Fremont Inc. |
Human anti-IL-8 antibodies, derived from immunized xenomice
|
|
CA2219486A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
|
EP0845043B1
(en)
|
1995-07-28 |
2007-06-27 |
Marie Curie Cancer Care |
Transport proteins and their uses
|
|
GB9520822D0
(en)
|
1995-10-11 |
1995-12-13 |
Wellcome Found |
Therapeutically active compounds
|
|
US5733920A
(en)
|
1995-10-31 |
1998-03-31 |
Mitotix, Inc. |
Inhibitors of cyclin dependent kinases
|
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
|
ES2183905T3
(es)
|
1995-12-20 |
2003-04-01 |
Hoffmann La Roche |
Inhibidores de metaloproteasa de matriz.
|
|
WO1997030174A1
(en)
|
1996-02-20 |
1997-08-21 |
Sloan-Kettering Institute For Cancer Research |
Combinations of pkc inhibitors and therapeutic agents for treating cancers
|
|
ATE211134T1
(de)
|
1996-03-05 |
2002-01-15 |
|
4-anilinochinazolin derivate
|
|
US6087366A
(en)
|
1996-03-07 |
2000-07-11 |
The Trustees Of Columbia University In The City Of New York |
Use of flavopiridol or a pharmaceutically acceptable salt thereof for inhibiting cell damage or cell death
|
|
US5849733A
(en)
|
1996-05-10 |
1998-12-15 |
Bristol-Myers Squibb Co. |
2-thio or 2-oxo flavopiridol analogs
|
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
JP4386967B2
(ja)
|
1996-07-13 |
2009-12-16 |
グラクソ、グループ、リミテッド |
プロテインチロシンキナーゼ阻害剤としての縮合複素環式化合物
|
|
ES2191187T3
(es)
|
1996-07-13 |
2003-09-01 |
Glaxo Group Ltd |
Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
|
|
HUP9903014A3
(en)
|
1996-07-18 |
2000-08-28 |
Pfizer |
Phosphinate derivatives having matrix metalloprotease inhibitor effect and medicaments containing the same
|
|
US6153609A
(en)
|
1996-08-23 |
2000-11-28 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
|
US5965703A
(en)
|
1996-09-20 |
1999-10-12 |
Idun Pharmaceuticals |
Human bad polypeptides, encoding nucleic acids and methods of use
|
|
US5908934A
(en)
|
1996-09-26 |
1999-06-01 |
Bristol-Myers Squibb Company |
Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs
|
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
|
AU5131998A
(en)
|
1997-01-06 |
1998-08-03 |
Pfizer Inc. |
Cyclic sulfone derivatives
|
|
ES2202796T3
(es)
|
1997-02-03 |
2004-04-01 |
Pfizer Products Inc. |
Derivados de acidos arilsulfonilaminohidroxamicos.
|
|
DE69839338T2
(de)
|
1997-02-05 |
2008-07-10 |
Warner-Lambert Company Llc |
Pyrido (2,3-d) pyrimidine und 4-amino-pyrimidine als inhibitoren der zellulären proliferation
|
|
JP2000507975A
(ja)
|
1997-02-07 |
2000-06-27 |
ファイザー・インク |
Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
|
|
BR9807678A
(pt)
|
1997-02-11 |
2000-02-15 |
Pfizer |
Derivados de ácidos arilsulfonil-hidroxâmicos
|
|
GB9704444D0
(en)
|
1997-03-04 |
1997-04-23 |
Isis Innovation |
Non-invasive prenatal diagnosis
|
|
JP2002511852A
(ja)
|
1997-05-07 |
2002-04-16 |
スージェン・インコーポレーテッド |
蛋白質キナーゼ活性の調節剤としての２−インドリノン誘導体
|
|
AU734009B2
(en)
|
1997-05-30 |
2001-05-31 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
|
ID23668A
(id)
|
1997-08-08 |
2000-05-11 |
Pfizer Prod Inc |
Turunan asam ariloksiarilsulfonilamino hidroksamat
|
|
ATE368665T1
(de)
|
1997-08-22 |
2007-08-15 |
Astrazeneca Ab |
Oxindolylchinazolinderivate als angiogenesehemmer
|
|
US7064193B1
(en)
|
1997-09-17 |
2006-06-20 |
The Walter And Eliza Hall Institute Of Medical Research |
Therapeutic molecules
|
|
CA2303830A1
(en)
|
1997-09-26 |
1999-04-08 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
|
WO1999016787A1
(en)
|
1997-09-26 |
1999-04-08 |
Washington University |
Cell death agonists
|
|
NZ520093A
(en)
|
1997-11-11 |
2004-03-26 |
Pfizer Prod Inc |
Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
|
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
DE19802449A1
(de)
|
1998-01-23 |
1999-07-29 |
Hoechst Marion Roussel De Gmbh |
Verfahren zur Herstellung von (-)cis-3-Hydroxy-1-methyl-4-(2,4,6-trimethoxypyhenyl)-piperidin
|
|
US6437136B2
(en)
|
1998-01-23 |
2002-08-20 |
Aventis Pharma Deutschland Gmbh |
Process for the preparation of (−)cis-3-hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)piperidine
|
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
|
DE19809649A1
(de)
|
1998-03-06 |
1999-09-09 |
Hoechst Marion Roussel De Gmbh |
Verfahren zur enzymatischen Enantiomeren-Trennung von 3(R)- und 3(S)-Hydroxy-1-methyl-4-(2,4,6-trimethoxyphenyl)-1,2,3,6-tetrahydro-pyridin bzw. der Carbonsäureester
|
|
JP4462654B2
(ja)
|
1998-03-26 |
2010-05-12 |
ソニー株式会社 |
映像素材選択装置及び映像素材選択方法
|
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
|
US20020029391A1
(en)
|
1998-04-15 |
2002-03-07 |
Claude Geoffrey Davis |
Epitope-driven human antibody production and gene expression profiling
|
|
IL139934A
(en)
|
1998-05-29 |
2007-10-31 |
Sugen Inc |
History 2 - Indulinone converted to pyrrole and pharmaceutical preparations containing them
|
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
|
FR2780056B1
(fr)
|
1998-06-18 |
2000-08-04 |
Hoechst Marion Roussel Inc |
Nouveau procede de preparation de derives de la 4-phenyl-1-2 3,6-tetrahydropyridine et les produits imtermediaires mis en oeuvre
|
|
WO2000006134A2
(en)
|
1998-07-30 |
2000-02-10 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
|
|
US6268499B1
(en)
|
1998-08-10 |
2001-07-31 |
Hoffman-La Roche Inc. |
Process and intermediates for preparation of substituted piperidine-epoxides
|
|
WO2000012071A2
(de)
|
1998-08-29 |
2000-03-09 |
Miklos Ghyczy |
Pharmazeutisches und/oder diätetisches produkt
|
|
ES2213985T3
(es)
|
1998-11-05 |
2004-09-01 |
Pfizer Products Inc. |
Derivados de hidroxiamida de acido 5-oxo-pirrolidin-2-carboxilico.
|
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
|
US6399633B1
(en)
|
1999-02-01 |
2002-06-04 |
Aventis Pharmaceuticals Inc. |
Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
|
|
EP1210098A1
(en)
|
1999-04-07 |
2002-06-05 |
Thomas Jefferson University |
Enhancement of peptide cellular uptake
|
|
US6511993B1
(en)
|
1999-06-03 |
2003-01-28 |
Kevin Neil Dack |
Metalloprotease inhibitors
|
|
AU6906100A
(en)
|
1999-08-16 |
2001-03-13 |
Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The |
Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis
|
|
US6576647B2
(en)
|
2000-01-18 |
2003-06-10 |
Aventis Pharmaceuticals Inc. |
Pseudopolymorph of (—)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy -1-methyl)piperidinyl]-4H-1-benzopyran-4-one
|
|
US6821990B2
(en)
|
2000-01-18 |
2004-11-23 |
Aventis Pharma Deutschland Gmbh |
Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5, 7-dihydroxy-8 [4R-(3S-hydroxy-1-M ethyl) piperidinyl]-4H-1-benzopyran-4-one
|
|
DE122008000002I1
(de)
|
2000-02-15 |
2008-04-17 |
Sugen Inc |
Pyrrol substituierte indolin-2-on protein kinase inhibitoren
|
|
WO2001080896A2
(en)
|
2000-04-21 |
2001-11-01 |
Arch Development Corporation |
Flavopiridol drug combinations and methods with reduced side effects
|
|
WO2002020568A2
(en)
|
2000-09-06 |
2002-03-14 |
Abbott Laboratories |
Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins
|
|
JP2004538247A
(ja)
*
|
2000-12-08 |
2004-12-24 |
ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー |
セミカルバジド及びサイクリン依存キナーゼ阻害剤
|
|
WO2002069995A2
(en)
|
2001-02-16 |
2002-09-12 |
Medical College Of Georgia Research Institute, Inc. |
Use of trail and antiprogestins for treating cancer
|
|
AU2002303164A1
(en)
|
2001-03-23 |
2002-10-08 |
Protarga, Inc. |
Fatty amine drug conjugates
|
|
EP1423107B1
(en)
|
2001-03-23 |
2012-05-09 |
Luitpold Pharmaceuticals, Inc. |
Fatty alcohol drug conjugates
|
|
WO2003027237A2
(en)
|
2001-09-24 |
2003-04-03 |
Blood Center Research Foundation |
Method of modulating or examining ku70 levels in cells
|
|
KR20030026069A
(ko)
|
2001-09-24 |
2003-03-31 |
주식회사 엘지생명과학 |
티엔에프계 단백질과 플라보피리돌의 조합에 의한 암세포특이적인 세포사멸 유도용 조성물
|
|
AU2002361589A1
(en)
|
2001-11-06 |
2003-05-19 |
Enanta Pharmaceuticals, Inc. |
Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
|
|
WO2003057158A2
(en)
|
2001-12-31 |
2003-07-17 |
Dana-Farber Cancer Institute, Inc. |
Method of treating apoptosis and compositions thereof
|
|
CA2478047C
(en)
|
2002-03-01 |
2014-01-21 |
Immunomedics, Inc. |
Rs7 antibodies
|
|
US20040106647A1
(en)
|
2002-06-28 |
2004-06-03 |
Schneider Michael D. |
Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy
|
|
WO2004022580A2
(en)
|
2002-09-09 |
2004-03-18 |
Dana-Farber Cancer Institute, Inc. |
Bh3 peptides and method of use thereof
|
|
US20070032417A1
(en)
|
2002-12-24 |
2007-02-08 |
Walter And Eliza Hall Institute Of Medical Research |
Peptides and therapeutic uses thereof
|
|
JP2006524710A
(ja)
|
2003-04-25 |
2006-11-02 |
ギリアード サイエンシーズ， インコーポレイテッド |
キナーゼインヒビターホスホネート抱合体
|
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
|
GB0315259D0
(en)
|
2003-06-30 |
2003-08-06 |
Cyclacel Ltd |
Use
|
|
MXPA06000508A
(es)
|
2003-07-18 |
2006-04-05 |
Amgen Inc |
Agentes de union especifica al factor del crecimiento de los hepatocitos.
|
|
CN1302004C
(zh)
|
2003-08-22 |
2007-02-28 |
浙江海正药业股份有限公司 |
一种阿糖胞苷的制备方法
|
|
PL1680443T3
(pl)
|
2003-11-05 |
2014-02-28 |
Dana Farber Cancer Inst Inc |
Stabilizowane alfa-helikalne peptydy i ich zastosowanie
|
|
WO2006069186A2
(en)
|
2004-12-22 |
2006-06-29 |
The Ohio State Research Foundation |
Small molecule bcl-xl/bcl-2 binding inhibitors
|
|
WO2006101846A1
(en)
|
2005-03-16 |
2006-09-28 |
Aventis Pharmaceuticals Inc. |
Dosing regimen of flavopiridol for treating cancer in particular cll
|
|
WO2006099667A1
(en)
|
2005-03-21 |
2006-09-28 |
The Walter And Eliza Hall Institute Of Medical Research |
Prophylactic and therapeutic agents and uses therefor
|
|
US7750000B2
(en)
|
2005-09-02 |
2010-07-06 |
Bayer Schering Pharma Ag |
Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
|
|
EP2008106A2
(en)
|
2006-03-31 |
2008-12-31 |
Dana-Farber Cancer Institute |
Methods of determining cellular chemosensitivity
|
|
US20090142337A1
(en)
*
|
2006-05-08 |
2009-06-04 |
Astex Therapeutics Limited |
Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
|
|
US9360473B2
(en)
|
2006-08-16 |
2016-06-07 |
Eutropics Pharmaceuticals, Inc. |
Assay system to identify therapeutic agents
|
|
MX2009004019A
(es)
*
|
2006-10-19 |
2009-06-19 |
Signal Pharm Llc |
Compuestos heteroarilo, composiciones de los mismos, y uso de los mismos como inhibidores de proteina cinasa.
|
|
KR20090129434A
(ko)
|
2007-03-01 |
2009-12-16 |
수퍼젠, 인크. |
피리미딘-2,4-디아민 유도체 및 ｊａｋ2 키나제 억제제로서의 이의 용도
|
|
GB0706633D0
(en)
*
|
2007-04-04 |
2007-05-16 |
Cyclacel Ltd |
Combination
|
|
ATE538652T1
(de)
|
2007-05-15 |
2012-01-15 |
Piramal Life Sciences Ltd |
Synergistische pharmazeutische kombination für die behandlung von krebs
|
|
RU2438664C2
(ru)
|
2007-05-15 |
2012-01-10 |
Пирамал Лайф Сайнсиз Лимитед |
Синергическая фармацевтическая комбинация для лечения рака
|
|
WO2009014642A1
(en)
|
2007-07-19 |
2009-01-29 |
Amgen Inc. |
Combination of a de novo purine biosynthesis inhibitor and a cyclin dependent kinase inhibitor for the treatment of cancer
|
|
WO2009042237A2
(en)
|
2007-09-26 |
2009-04-02 |
Dana Farber Cancer Institute |
Methods and compositions for modulating bcl-2 family polypeptides
|
|
EP2249831A2
(en)
|
2007-12-10 |
2010-11-17 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
|
|
TWI378781B
(en)
|
2008-03-12 |
2012-12-11 |
Jung Tang Huang |
A belt integrated with stress sensing and output reaction
|
|
EP2304047A4
(en)
|
2008-05-07 |
2012-12-26 |
Eutropics Pharmaceuticals Inc |
ANTIBODIES TAKEN UPON HETERODIMES OF THE BCL-2 FAMILY AND THEIR USES
|
|
PL2307002T3
(pl)
*
|
2008-06-09 |
2013-05-31 |
Cyclacel Ltd |
Kombinacje sapacytabiny lub cndac z inhibitorami metylotransferazy dna, takimi jak decytabina i prokaina
|
|
TWI453207B
(zh)
*
|
2008-09-08 |
2014-09-21 |
Signal Pharm Llc |
胺基三唑并吡啶，其組合物及使用其之治療方法
|
|
JP2012517241A
(ja)
|
2009-02-11 |
2012-08-02 |
アボット・ラボラトリーズ |
Ｂｃｌ−２ファミリー阻害剤耐性腫瘍及び癌を有する被験者を同定、分類及びモニターするための方法及び組成物
|
|
ES2738700T3
(es)
|
2009-02-13 |
2020-01-24 |
Immunomedics Inc |
Inmunoconjugados con un enlace escindible intracelularmente
|
|
WO2010147961A1
(en)
|
2009-06-15 |
2010-12-23 |
Precision Therapeutics, Inc. |
Methods and markers for predicting responses to chemotherapy
|
|
WO2011088137A2
(en)
|
2010-01-12 |
2011-07-21 |
H. Lee Moffitt Cancer Center & Research Institute |
Bad pathway gene signature
|
|
US8372819B2
(en)
|
2010-04-11 |
2013-02-12 |
Salk Institute For Biological Studies |
Methods and compositions for targeting skip
|
|
MX373121B
(es)
|
2010-05-14 |
2020-04-30 |
Dana Farber Cancer Inst Inc |
Composiciones y metodos para el tratamiento de leucemia.
|
|
SG180031A1
(en)
|
2010-10-15 |
2012-05-30 |
Agency Science Tech & Res |
Combination treatment of cancer
|
|
WO2012088438A1
(en)
|
2010-12-22 |
2012-06-28 |
Eutropics Pharmaceuticals, Inc. |
Compositions and methods useful for treating diseases
|
|
WO2012122370A2
(en)
|
2011-03-08 |
2012-09-13 |
Eutropics Pharmaceuticals, Inc. |
Compositions and methods useful for treating diseases
|
|
US20140113919A1
(en)
|
2011-06-14 |
2014-04-24 |
Novartis Ag |
Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
|
|
EP2561867A1
(en)
|
2011-08-22 |
2013-02-27 |
Lead Discovery Center GmbH |
CDK9 inhibitors in the treatment of midline carcinoma
|
|
US9012215B2
(en)
|
2011-09-22 |
2015-04-21 |
The Johns Hopkins University |
Methods for identifying leukemia stem cells and distinguishing them from normal hematopietic stem cells in patients with acute myeloid leukemia: uses in diagnosis, treatment, and research
|
|
US20130122492A1
(en)
|
2011-11-14 |
2013-05-16 |
Kellbenx Inc. |
Detection, isolation and analysis of rare cells in biological fluids
|
|
WO2013082660A1
(en)
|
2011-12-09 |
2013-06-13 |
Alfred Health |
Prediction method
|
|
WO2013138702A2
(en)
|
2012-03-15 |
2013-09-19 |
Bristol-Myers Squibb Company |
Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
|
|
AU2013235425B2
(en)
|
2012-03-20 |
2017-09-21 |
Dana Farber Cancer Institute, Inc. |
Inhibition of MCL-1 and/or BFL-1/A1
|
|
CN104541170A
(zh)
|
2012-05-10 |
2015-04-22 |
尤特罗皮克斯制药股份有限公司 |
对癌症的代理功能性诊断测试
|
|
WO2013182519A1
(en)
|
2012-06-04 |
2013-12-12 |
Universitaet Basel |
Combination of lysosomotropic or autophagy modulating agents and a gsk-3 inhibitor for treatment of cancer
|
|
WO2013188355A1
(en)
|
2012-06-12 |
2013-12-19 |
Merck Sharp & Dohme Corp. |
Cdk inhibitor for treating refractory chronic lymphocytic leukemia
|
|
WO2013188978A1
(en)
|
2012-06-20 |
2013-12-27 |
Cytospan Technologies Corporation |
Apparatus and method for quantification of replicative lifespan and observation of senescene
|
|
IN2014DN11205A
(enExample)
|
2012-06-20 |
2015-10-02 |
Eutropics Pharmaceuticals Inc |
|
|
EP2898327A1
(en)
|
2012-09-19 |
2015-07-29 |
Dana-Farber Cancer Institute, Inc. |
Dynamic bh3 profiling
|
|
US9241941B2
(en)
|
2012-09-20 |
2016-01-26 |
Memorial Sloan-Kettering Cancer Center |
Methods for treatment of lymphomas with mutations in cell cycle genes
|
|
CN104812756A
(zh)
|
2012-09-26 |
2015-07-29 |
曼凯德公司 |
多激酶通路抑制剂
|
|
CA2887129A1
(en)
*
|
2012-10-09 |
2014-04-17 |
Igenica, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
|
EP2913053A4
(en)
|
2012-10-23 |
2016-05-25 |
Teijin Pharma Ltd |
THERAPEUTIC OR PROPHYLACTIC AGENT FOR TUMOR LYING SYNDROME
|
|
US20140287932A1
(en)
|
2012-10-25 |
2014-09-25 |
Whitehead Institute For Biomedical Research |
Super-enhancers and methods of use thereof
|
|
CA3105575A1
(en)
|
2013-01-15 |
2014-07-24 |
Aragon Pharmaceuticals, Inc. |
Androgen receptor modulator and uses thereof
|
|
JP2016526892A
(ja)
|
2013-07-18 |
2016-09-08 |
ユートロピクス ファーマシューティカルズ， インコーポレイテッド |
示差的ｂｈ３ミトコンドリアプロファイリング
|
|
WO2015017788A1
(en)
|
2013-08-01 |
2015-02-05 |
Eutropics Pharmaceuticals, Inc. |
Method for predicting cancer sensitivity
|
|
CA2922503C
(en)
|
2013-09-19 |
2021-10-26 |
Dana-Farber Cancer Institute, Inc. |
Methods of bh3 profiling
|
|
EP3049443A4
(en)
|
2013-09-27 |
2017-04-05 |
Immunomedics, Inc. |
Anti-trop-2 antibody-drug conjugates and uses thereof
|
|
AU2014342269B2
(en)
|
2013-10-30 |
2020-02-27 |
Eutropics Pharmaceuticals, Inc. |
Methods for determining chemosensitivity and chemotoxicity
|
|
KR20160072261A
(ko)
|
2013-11-08 |
2016-06-22 |
다나-파버 캔서 인스티튜트 인크. |
브로모도메인 및 엑스트라-말단 (bet) 단백질 저해제를 이용한 암 치료를 위한 조합 요법
|
|
WO2015130585A1
(en)
|
2014-02-28 |
2015-09-03 |
Merck Sharp & Dohme Corp. |
Method for treating cancer
|
|
WO2015161247A1
(en)
*
|
2014-04-17 |
2015-10-22 |
Igenica Biotherapeutics, Inc. |
Humanized anti-c16orf54 antibodies and methods of use thereof
|
|
JP6839074B2
(ja)
|
2014-09-17 |
2021-03-03 |
ノバルティス アーゲー |
養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
|
|
EP3206749B1
(en)
|
2014-10-14 |
2021-09-08 |
The Regents of the University of California |
The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation
|
|
AU2015342813B2
(en)
|
2014-11-07 |
2021-04-22 |
Sumitomo Pharma Oncology, Inc. |
Methods to target transcriptional control at super-enhancer regions
|
|
EP3245301B1
(en)
|
2015-01-12 |
2020-11-11 |
Eutropics Pharmaceuticals, Inc. |
Context dependent diagnostics test for guiding cancer treatment
|
|
WO2016133910A1
(en)
|
2015-02-17 |
2016-08-25 |
Cantex Pharmaceuticals, Inc. |
Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
|
|
AU2016232833A1
(en)
|
2015-03-18 |
2017-10-12 |
Dana-Farber Cancer Institute, Inc. |
Selective Mcl-1 binding peptides
|
|
EP3274467A4
(en)
|
2015-03-24 |
2018-10-31 |
Eutropics Pharmaceuticals, Inc. |
Surrogate functional biomarker for solid tumor cancer
|
|
WO2016161248A1
(en)
|
2015-04-02 |
2016-10-06 |
Tolero Pharmaceuticals, Inc. |
Targeting pim kinases in combination with btk inhibition
|
|
BR112017022666A8
(pt)
|
2015-04-20 |
2022-10-18 |
Tolero Pharmaceuticals Inc |
Preparando resposta à alvocidib por perfilamento mitocondrial
|
|
JP6802185B2
(ja)
|
2015-04-27 |
2020-12-16 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
ハイスループットｂｈ３プロファイリング：少量の細胞でのｂｈ３プロファイルのための迅速かつ拡大縮小可能な技術
|
|
CN111349118B
(zh)
|
2015-05-18 |
2023-08-22 |
住友制药肿瘤公司 |
具有增加的生物利用度的阿伏西地前药
|
|
RU2759963C2
(ru)
|
2015-08-03 |
2021-11-19 |
Сумитомо Даиниппон Фарма Онколоджи, Инк. |
Комбинированные терапии для лечения рака
|
|
US20190077840A1
(en)
|
2015-10-30 |
2019-03-14 |
Massachusetts Institute Of Technology |
Selective mcl-1 binding peptides
|
|
US9782232B1
(en)
|
2016-04-25 |
2017-10-10 |
Novartis Ag |
Automated intraocular pressure tamponade
|
|
CN105919955A
(zh)
|
2016-06-13 |
2016-09-07 |
佛山市腾瑞医药科技有限公司 |
一种鲁索利替尼制剂及其应用
|
|
US20190336504A1
(en)
|
2016-07-15 |
2019-11-07 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
US11279694B2
(en)
|
2016-11-18 |
2022-03-22 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
|
JP6619519B2
(ja)
|
2016-12-19 |
2019-12-11 |
トレロ ファーマシューティカルズ， インコーポレイテッド |
プロファイリングペプチドおよび感受性プロファイリングのための方法
|
|
WO2019055579A1
(en)
|
2017-09-12 |
2019-03-21 |
Tolero Pharmaceuticals, Inc. |
TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR
|
|
WO2019200243A1
(en)
|
2018-04-13 |
2019-10-17 |
Tolero Pharmaceuticals, Inc. |
Cyclin-dependent kinase inhibitors in combination with anthracyclines for treatment of cancer
|
|
US20210277037A1
(en)
|
2018-06-21 |
2021-09-09 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Deuterated alvocidib and alvocidib prodrugs
|